ISB News

ISB Gets $1.7M to Study Cancer Drug Resistance

Congratulations to the Sui Huang Lab at ISB which has received a five-year $1.7 million R01 award from the National Institutes of Health and National Institute for General Medical Sciences to study cancer sub-population dynamics to understand and develop drugs to inhibit lethal cancer-drug resistance. The project proposal states that the work will: “develop a quantitative and formal framework for describing the temporal evolution of cell phenotype distribution in a tumor cell population to address the unmet need to understand how heterogeneity and subpopulation dynamics of tumor cell populations affect drug response.”

Learn more:

Cancer Treatment: A Systems Approach

New Principle of Chemo-Resistance Sheds Light on Cancer Evasiveness

Biggest Family Tree of Human Cells May Help Develop Cell-Replacement Therapies

 


 

Recent Articles

  • Dr. Sid Venkatesh

    Sid Venkatesh Publishes Co-First Authored Paper in Science

    ISB Assistant Professor Dr. Sid Venkatesh is the co-first author of a paper in the journal Science. While at Washington University in St. Louis, Venkatesh and colleagues identified a novel gut microbial enzyme that impacts satiety-related signaling pathways in undernourished children treated with microbiota-directed complementary foods.

  • AmeriCorps Member Faduma Hussein Joins ISB as Public Health Ambassador Coordinator

    Faduma Hussein recently joined the ISB Education team as the Public Health Ambassador Coordinator, becoming only the fourth AmeriCorps member to serve at ISB. In this Q&A, she shares insights into her education, what drew her to ISB, career aspirations, and more.

  • Spotlight on ISB Education graphic

    2024-25 School Year ISB Education Highlights

    In the first installment of the 2024-25 academic year roundup, we highlight some of the top projects the ISB Education team is working on. In October, we welcomed new team members, developed a new format for our popular “Systems Are Everywhere!” workshop, and more.